Cargando…

Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral i...

Descripción completa

Detalles Bibliográficos
Autores principales: Datsi, Angeliki, Sorg, Rüdiger V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592940/
https://www.ncbi.nlm.nih.gov/pubmed/34795675
http://dx.doi.org/10.3389/fimmu.2021.770390
_version_ 1784599593094217728
author Datsi, Angeliki
Sorg, Rüdiger V.
author_facet Datsi, Angeliki
Sorg, Rüdiger V.
author_sort Datsi, Angeliki
collection PubMed
description Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral immune response. Numerous DCV trials have been performed, vaccinating hundreds of GBM patients and confirming feasibility and safety. Many of these studies reported induction of an antitumoral immune response and indicated improved survival after DCV. However, two controlled randomized trials failed to detect a survival benefit. This raises the question of whether the promising concept of DCV may not hold true or whether we are not yet realizing the full potential of this therapeutic approach. Here, we discuss the results of recent vaccination trials, relevant parameters of the vaccines themselves and of their application, and possible synergies between DCV and other therapeutic approaches targeting the immunosuppressive microenvironment of GBM.
format Online
Article
Text
id pubmed-8592940
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85929402021-11-17 Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End Datsi, Angeliki Sorg, Rüdiger V. Front Immunol Immunology Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral immune response. Numerous DCV trials have been performed, vaccinating hundreds of GBM patients and confirming feasibility and safety. Many of these studies reported induction of an antitumoral immune response and indicated improved survival after DCV. However, two controlled randomized trials failed to detect a survival benefit. This raises the question of whether the promising concept of DCV may not hold true or whether we are not yet realizing the full potential of this therapeutic approach. Here, we discuss the results of recent vaccination trials, relevant parameters of the vaccines themselves and of their application, and possible synergies between DCV and other therapeutic approaches targeting the immunosuppressive microenvironment of GBM. Frontiers Media S.A. 2021-11-02 /pmc/articles/PMC8592940/ /pubmed/34795675 http://dx.doi.org/10.3389/fimmu.2021.770390 Text en Copyright © 2021 Datsi and Sorg https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Datsi, Angeliki
Sorg, Rüdiger V.
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
title Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
title_full Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
title_fullStr Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
title_full_unstemmed Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
title_short Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
title_sort dendritic cell vaccination of glioblastoma: road to success or dead end
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592940/
https://www.ncbi.nlm.nih.gov/pubmed/34795675
http://dx.doi.org/10.3389/fimmu.2021.770390
work_keys_str_mv AT datsiangeliki dendriticcellvaccinationofglioblastomaroadtosuccessordeadend
AT sorgrudigerv dendriticcellvaccinationofglioblastomaroadtosuccessordeadend